Popular search terms:
CSL's Financial Results
Please click the link below to view our most recent and historic Full Year and Half Year Financial Results information.
More InformationSearch Results
154 results found-
We announced our 2021 Half Year Financial Results on Thursday, 18th February 2021 (AEDT).
https://www.csl.com/investors/half-year-results-2021 -
This written declaration was received by the Board prior to its approval of the full-year and half-year financial statements for the financial year ended 30 June 2021.
https://www.csl.com/-/media/csl/documents/csl-governance-docs/corporate-governance-statement-2021.pdf -
11 September Record date for fi nal dividend 9 October Final dividend paid 14 October Annual General Meeting 31 December Half Year ends Find out more 2021 Key Dates CSL.com 16 February Half year profi t and interim dividend announcement 4 March Shares traded ex-dividend About this report 5 March Record date for interim dividend This is CSL's second annual report where we have combined our 1 April Interim dividend paid financial and non-financial performance in one comprehensive 30 June Full Year ends account, linking our sustainability and strategic priorities to our business results.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
1 Chairman and CEO's Letter 2 CSL Calendar 2 2019 Performance 4 2019 Business performance and highlights 4 14 August Annual profi t and fi nal dividend announcement Financial highlights 5 10 September Shares traded ex-dividend 3 Our Company 6 11 September Record date for fi nal dividend Our businesses 6 Our locations 7 11 October Final dividend paid Our product portfolio 8 16 October Annual General Meeting Our research and development pipeline 9 31 December Half year ends 4 CSL Strategy 10 2020 How we create value 12 12 February Half year profi t and interim dividend 5 Powered by Innovation 14 announcement Collaboration with and funding of medical research 14 11 March Shares traded ex-dividend Investment in research and development pipeline 14 12 March Record date for interim dividend Focus on selected therapeutic areas - specialisation 15 9 April Interim dividend paid New products to market 16 30 June Year ends Clinical trials in process and new 18 19 August Annual profi t and fi nal dividend announcement Clinical trial transparency 18 10 September Shares traded ex-dividend Leveraging advanced analytics and artifi cial intelligence 19 11 September Record date for fi nal dividend Innovation across the value chain 19 9 October Final dividend paid 6 Global Reach and Impact 21 14 October Annual General Meeting Global reach and focus 21 31 December Half year ends Donor management 24 Focus on effi ciency, standardised manufacturing 24 processes and integrated supply chain Annual General Meeting Environment health and safety 25 Wednesday, 16 October 2019 at 1 p.m. Supply chain management 25 7 A Trusted Health Partner 26 New city and venue Product quality and safety 26 Value and access 27 The Westin Sydney, Grand Ballroom Public policy engagement 28 1 Martin Place Secure and reliable supply 29 Sydney NSW 2000 Pandemic and emergency response 29 Relationships with healthcare professionals 29 Share Registry regulators and patient groups Computershare Investor Services Pty Limited Responsible marketing and promotion 29 Postal Address:
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
FVIII half-life regulated by VWF •
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2016.pdf -
Once we "About half of my Alprolix patients have get to 21%, you know the patient is very switched to IDELVION® now.
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2017.pdf -
We will announced our 2020 Half Year Results on Wednesday, 12th February 2020 (AEDT)
https://www.csl.com/investors/half-year-results-2020